Advertisement
Screener

Scilex Holding Company (SCLX) Increase (Decrease) in Accounts Receivable

2.8 / 5 stars · 68/120 Roast Me

Scilex Holding Company Increase (Decrease) in Accounts Receivable

Scilex Holding Company (SCLX) reported Increase (Decrease) in Accounts Receivable of -$8.73 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-14

  • Scilex Holding Company increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was -$4.13M, a 167.26% decline year-over-year.
  • Scilex Holding Company increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$4.60M.
  • Scilex Holding Company increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $664.00K, a 91.80% decline year-over-year.
  • Scilex Holding Company increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was -$4.83M.
  • Scilex Holding Company increase (decrease) in accounts receivable for fiscal 2025 was -$13.84M, a 320.79% decline from fiscal 2024.
  • Scilex Holding Company increase (decrease) in accounts receivable for fiscal 2024 was $6.27M, a 53.09% decline from fiscal 2023.
  • Scilex Holding Company increase (decrease) in accounts receivable for fiscal 2023 was $13.36M, a 91.75% increase from fiscal 2022.
  • Scilex Holding Company increase (decrease) in accounts receivable for fiscal 2022 was $6.97M, a 510.16% increase from fiscal 2021.
Period endIncrease (Decrease) in Accounts Receivable 3 monthIncrease (Decrease) in Accounts Receivable 6 monthIncrease (Decrease) in Accounts Receivable 9 monthIncrease (Decrease) in Accounts Receivable 12 month
2026-06-30-$4.13M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14
-$8.73M
10-Q · filed 2026-08-14
-$8.07M
derived: sum of 3 quarters · filed 2026-08-14
-$12.89M
derived: sum of 4 quarters · filed 2026-08-14
2026-03-31-$4.60M
10-Q · filed 2026-05-20
-$3.93M
derived: sum of 2 quarters · filed 2026-05-20
-$8.76M
derived: sum of 3 quarters · filed 2026-05-20
-$2.61M
derived: sum of 4 quarters · filed 2026-08-14
2025-12-31$664.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10
-$4.16M
derived: sum of 2 quarters · filed 2026-04-10
$1.99M
derived: sum of 3 quarters · filed 2026-08-14
-$13.84M
10-K · filed 2026-04-10
2025-09-30-$4.83M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14
$1.32M
derived: sum of 2 quarters · filed 2026-08-14
-$14.50M
10-Q · filed 2025-11-14
-$6.40M
derived: sum of 4 quarters · filed 2026-08-14
2025-06-30$6.15M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14
-$9.68M
10-Q · filed 2026-08-14
-$1.58M
derived: sum of 3 quarters · filed 2026-08-14
-$6.82M
derived: sum of 4 quarters · filed 2026-08-14
2025-03-31-$15.82M
10-Q · filed 2026-05-20
-$7.72M
derived: sum of 2 quarters · filed 2026-05-20
-$12.96M
derived: sum of 3 quarters · filed 2026-05-20
-$4.67M
derived: sum of 4 quarters · filed 2026-05-20
2024-12-31$8.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10
$2.86M
derived: sum of 2 quarters · filed 2026-04-10
$11.15M
derived: sum of 3 quarters · filed 2026-04-10
$6.27M
10-K · filed 2026-04-10
2024-09-30-$5.24M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14
$3.05M
derived: sum of 2 quarters · filed 2025-11-14
-$1.83M
10-Q · filed 2025-11-14
$16.34M
derived: sum of 4 quarters · filed 2025-11-14
2024-06-30$8.29M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13
$3.41M
10-Q · filed 2025-08-13
$21.58M
derived: sum of 3 quarters · filed 2025-08-13
$10.44M
derived: sum of 4 quarters · filed 2025-08-13
2024-03-31-$4.88M
10-Q · filed 2025-05-14
$13.29M
derived: sum of 2 quarters · filed 2025-05-14
$2.15M
derived: sum of 3 quarters · filed 2025-05-14
$10.47M
derived: sum of 4 quarters · filed 2025-05-14
2023-12-31$18.17M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31
$7.03M
derived: sum of 2 quarters · filed 2025-03-31
$15.35M
derived: sum of 3 quarters · filed 2025-03-31
$13.36M
10-K · filed 2025-03-31
2023-09-30-$11.14M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-01-17
-$2.82M
derived: sum of 2 quarters · filed 2025-01-17
-$4.81M
10-Q · filed 2025-01-17
-$1.05M
derived: sum of 4 quarters · filed 2025-01-17
2023-06-30$8.32M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13
$6.33M
10-Q · filed 2024-08-13
$10.09M
derived: sum of 3 quarters · filed 2024-08-13
$11.67M
derived: sum of 4 quarters · filed 2024-08-13
2023-03-31-$1.99M
10-Q · filed 2024-05-13
$1.77M
derived: sum of 2 quarters · filed 2024-05-13
$3.34M
derived: sum of 3 quarters · filed 2024-05-13
$3.83M
derived: sum of 4 quarters · filed 2024-05-13
2022-12-31$3.76M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12
$5.34M
derived: sum of 2 quarters · filed 2024-03-12
$5.82M
derived: sum of 3 quarters · filed 2024-03-12
$6.97M
10-K · filed 2024-03-12
2022-09-30$1.57M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14
$2.06M
derived: sum of 2 quarters · filed 2023-11-14
$3.21M
10-Q · filed 2023-11-14
2022-06-30$488.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11
$1.63M
10-Q · filed 2023-08-11
2022-03-31$1.14M
10-Q · filed 2023-05-12
2021-12-31$1.14M
10-K · filed 2024-03-12
2020-12-31$598.00K
10-K · filed 2023-03-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
Metagenomi Therapeutics, Inc. (MGX)United States$0.044B-0.48
LeonaBio, Inc. (LONA)United States$0.047B-0.61
Instil Bio, Inc. (TIL)United States$0.048B-1.73
Tevogen Inc. (TVGN)United States$0.049B
aTYR PHARMA INC (ATYR)United States$0.033B-0.98
Quince Therapeutics, Inc. (QNCX)United States$0.031B
CEL SCI CORP (CVM)United States$0.030B-0.81
Inmune Bio, Inc. (INMB)United States$0.056B-2.48
ImageneBio, Inc. (IMA)United States$0.056B-1.31
BioAtla, Inc. (BCAB)United States$0.058B-0.21